The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Nonfasting Remnant Cholesterol in a Real World Population

Table 1

Baseline characteristics of patient sample.

		Total Sample; N = 109
Age (years)		64.1 ± 11.7
Female		65 (60)
PCSK9 Inhibitor
Evolocumab 140mg		62 (57)
Alirocumab 75mg		23 (21)
Alirocumab 150 mg		24 (22)
ASCVD		98 (90)
Coronary		87
Peripheral		2
Cerebral		1
Polyvascular		2
Coronary calcium		6
FH without ASCVD		11 (10)
Diabetes		37 (34)
Lipid diagnosis ASCVD
Hypercholesterolemia alone		61 (56)
Combined hyperlipidemia		37 (34)
Therapy	Statin Intolerance	Any Statin	Any LLRx
ASCVD	78 (80)	20 (20)	44 (45)
FH	9 (82)	2 (18)	2 (18)

ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; LLRx, lipid lowering therapy; PCSK9, proprotein convertase subtilisin kexin 9.
Data presented as frequency (%) or mean ± SD.